CBG: Background information on cannabigerol

CBG Effects: What Is Known About Cannabigerol

Jona Decker von Jona Decker04.02.2026 7 Min. Lesezeit

Das Wichtigste in Kürze

The key facts at a glance

  • Cannabigerol (CBG) is a non-intoxicating cannabinoid and the precursor of many other cannabinoids.
  • Research into CBG is still at an early stage; robust studies in humans are largely lacking.
  • The effects described come mainly from laboratory and animal studies and do not allow any conclusions about products.
  • CBG flowers from CBDÍA are not a medicinal product and are not offered for health purposes.
Ein Astronaut während der Wirkung von CBG

What is known and what is not

Here you’ll find what is known so far about cannabigerol (CBG) and where research is still at an early stage. This article reports on the current state of research and does not make any claims of healing or effect. For health-related questions, medical advice is the right place to turn.

CBDÍA products are not medicinal products. This article summarises the state of research and makes no claims of healing, effect or usage recommendations. For health questions, medical advice helps.

If you’re wondering, “What is CBG?”, you’ve come across a cannabinoid from the hemp or cannabis plant that gets far less attention than CBD. CBG, short for cannabigerol, is considered an early precursor of various cannabinoids and is therefore of particular interest from a botanical and chemical point of view. In this guide, Jona Decker sets out what is known about CBG (cannabigerol) and which basics matter for a factual understanding. You can find an overview of the available strains in our CBG Flowers category.

The focus here is not on blanket promises about the effects of CBG, but on comprehensible information: how does CBG form in the plant, how does it differ chemically from CBD, and what matters when it comes to quality, analysis and classification? This provides a solid basis for putting statements about CBG into perspective.

What is CBG?

CBG stands for cannabigerol and belongs to the group of cannabinoids, the chemical compounds found in the cannabis plant. Anyone asking “What is CBG?” often comes across its classification as a precursor: CBG is closely related to CBGA, an acidic starting form from which, among other things, other cannabinoids can form as the plant matures. This is why CBG is usually present in only comparatively small amounts in many plants.

In the context of “CBG cannabigerol”, the focus is mainly on chemical properties and the distinction from well-known substances such as CBD or THC. CBG is not the same as CBD; the difference lies in the molecular structure, its occurrence in the plant and the respective scientific perspective. Searches for “CBG effects” should be understood factually: a possible effect of CBG is being researched; no established claims of benefit can be derived from this. It is therefore important to distinguish between laboratory findings, theoretical properties and substantiated statements about effects. Even compared with CBD, research into the properties of CBG remains a young field.

How does CBG form in the cannabis plant?

CBGA as a precursor

In the cannabis plant, the formation of many active compounds begins with CBGA, the acidic form of CBG. This compound is considered a central precursor from which various cannabinoids can form through the plant’s own enzymes. Depending on the plant’s genetic makeup, CBGA is converted, among other things, into precursors of THC, CBD or CBC. CBG (cannabigerol) is therefore biochemically closely linked to several other cannabinoids and is often described as a starting point in cannabinoid metabolism.

Why CBG is often only present in small amounts

Anyone asking “What is CBG?” quickly comes across an important point: CBG is usually present only in small amounts in mature plant material. The reason lies in the plant’s development. As the hemp plant grows, CBGA is continuously converted into other cannabinoids by enzymes. The longer this process runs, the less unchanged precursor remains. This is why many strains contain only low CBG concentrations by the end of the ripening phase.

Breeding and harvest timing

How much CBG remains in the plant depends heavily on the strain, growth stage and harvest window. Some breeding programmes are designed to limit the conversion of CBGA into other cannabinoids. An earlier harvest can also favour higher CBG levels, but at the same time changes the rest of the cannabinoid profile. Such differences are relevant for research because they show how dynamic the chemical composition of the cannabis plant is.

How is CBG obtained and tested?

Extraction from EU hemp strains

Extraction begins with EU-compliant hemp strains that are approved under the variety catalogue and must comply with defined THC limits. For CBG flowers, the specific plant batch is decisive: origin, growing area, harvest time and drying all influence how much CBG is present in the hemp plant. Controlled raw materials provide the basis for later analyses to remain traceable and for batches to be clearly identified.

Extraction and further processing

After harvesting, CBG is obtained from dried plant material and further processed depending on the intended product. Various extraction methods are common, for example using CO₂ or suitable solvents, followed by filtration, purification and, where applicable, concentration. CBG (cannabigerol) is present here together with further cannabinoids and plant compounds; processing aims to capture these components in a controlled way without leaving behind unwanted residues.

Analysis of cannabinoid and terpene profile

Whether CBG is present, and in what composition, is only shown by laboratory testing. CBG is quantified in the process; other cannabinoids, the terpene profile and possible residues are also examined. Batch testing plays an important role here: for each batch, a lab certificate can document the properties of the material, how high the THC content is and whether purity criteria are met. This means CBG is not only obtained, but also transparently verifiable.

CBG vs. CBD: what is the difference?

Is CBG better than CBD?

When it comes to CBG vs. CBD, it’s not about a blanket ranking. Both substances have their own properties and are considered separately in research. Anyone asking “What is CBG?” ends up with a cannabinoid that has a different chemical profile from CBD. The effects of CBG also cannot simply be transferred to CBD: effects, context of use and the available data must each be assessed separately.

Similarities between CBG and CBD

CBG (cannabigerol) and CBD both belong to the cannabinoids of the hemp plant. They are not the same, but share a plant origin and are related to other cannabinoids. CBD and CBG are obtained from plant material and then further processed depending on the product. Statements about effects and CBG experiences should remain cautious, since research into CBD, and especially into CBG, has not yet conclusively answered every question.

Differences in profile and availability

The most important difference between CBG and CBD lies in the quantity: CBD occurs far more often in many hemp strains, while the concentration of CBG is usually lower. Obtaining CBG can therefore be more involved. CBD is better known on the market, and CBD products are more widely available and more established. When it comes to CBG vs. CBD, it is therefore not only chemical properties that differ, but also availability, pricing and how well known each is. The possible effects of CBG and CBD are studied separately; other factors such as strain, extract and composition also play a role.

CBG flowers in Germany: what matters?

EU variety catalogue and THC limit

For CBG flowers in Germany, it is crucial that the hemp used comes from approved strains from the EU variety catalogue. In addition, the THC content must be below 0.3 percent. This limit forms an important legal and quality framework: only if THC is present in low amounts can the corresponding CBG products be classified as lawful in Germany.

Lab certificate per batch

A batch-specific lab certificate shows which cannabinoids are present in the respective CBG flowers and whether the THC level is below the limit. For consumers, this provides key orientation, because CBG can vary in natural products. Reputable products therefore disclose analysis values transparently, rather than making only general statements about CBG or THC.

Supply only to adults aged 18 and over

CBG flowers and comparable products should only be supplied to adults aged 18 and over. In Germany, this note is part of responsible handling of the category. Even where an offer is described as legal, this does not replace checking the origin, THC content and lab certificate; this is precisely where the relevant quality benchmark lies.

What role do analysis and research play?

Lab values instead of promises

With CBG (cannabigerol), verifiable lab values matter more than claims about the effects of CBG. Analyses show which cannabinoids are present in a sample, how high the proportion of CBG is, and whether THC is below the legally relevant limit. Terpene profiles and possible residues also provide indications of properties and quality. This allows products to be compared factually, without deriving a specific effect from individual measured values.

Market developments around CBG

Research into CBG is at an early stage and is examining, among other things, how various cannabinoids form in the plant. For the market, what matters most is that breeding and analytics are making CBG-rich strains more widely available. As a result, CBG flowers, extracts and other products with a documented cannabinoid profile are becoming more common. Compared with CBD or THC, however, the available data remains more limited. Market observations can show which strains are available; they do not, however, replace controlled research into effects or interactions with other cannabinoids.

Conclusion: CBG in factual terms

The question “What is CBG?” can be answered mainly in botanical and chemical terms: CBG (cannabigerol) is a cannabinoid closely linked to the development of other plant compounds. Compared with CBD, the formation, availability and property profile differ. Anyone interested in CBG flowers should therefore focus less on promises of benefit and more on transparent information about origin, analysis values and processing. This keeps the classification of CBG factual and comprehensible.

This article provides general information about CBG and replaces neither legal nor medical advice. The information is current as of August 2026. The corresponding products are supplied exclusively to adults aged 18 and over.


Our CBD flowers at a glance

View all
Sale
Sold Out

FAQ on the effects of CBG

No, the effect of CBG in humans has not yet been reliably proven. Cannabigerol is mainly studied in cell cultures and animal models; studies in humans are rare, small and short. Review articles therefore describe the body of research as limited. No statements about the benefit of a product can be derived from these findings. CBDÍA's CBG products are not medicinal products and are offered without any promise of effect.

There is no reliable information on this. For the question of how long the effect of CBG lasts, meaningful studies in humans are missing. Time frames circulating online are mostly based on assumptions carried over from CBD or on individual anecdotes. CBDÍA therefore does not state a duration of effect, because that would amount to a usage recommendation. What can be substantiated is only what a batch's certificate of analysis shows: the measured content of CBG, CBD and THC.

There is hardly any data on possible side effects of CBG, because studies in humans have so far been rare and small. A reliable statement on safety is not possible on this basis, either positive or negative. Anyone taking medication, pregnant, breastfeeding, or with health-related questions should discuss cannabinoids with a doctor. CBDÍA does not offer CBG products as medicinal products and makes no health-related claims about the effect of CBG.

Laboratory studies describe that cannabigerol can bind to several target structures, for example weakly to the cannabinoid receptors CB1 and CB2 as well as to other receptors and ion channels. These findings come predominantly from cell and animal experiments and describe mechanisms, not a proven effect of CBG in humans. How relevant they are outside the laboratory remains open. Such mechanistic data are therefore not suitable as a purchasing argument.

Because there is no reliable basis for it and CBG products are not medicinal products. A dosage recommendation would imply an effect of CBG that is not proven in humans. Cannabinoid extracts are also not approved as food in the EU (Novel Food). CBDÍA therefore states neither quantities nor methods of use, but instead discloses what can be measured: cannabinoid content, THC value and origin for each batch.

No. Claims about health benefits of CBG would be health-related advertising without approval. That's why CBDÍA describes CBG products through verifiable features: origin with country and cultivation type, industrial hemp from the EU variety catalogue, and a certificate of analysis for each batch with cannabinoid profile and a THC value under 0.3%. Anyone who reads specific promises about the effect of CBG online should ask for the source and assess it critically.

No. The certificate of analysis measures how much cannabigerol, CBD, THC and other cannabinoids a batch contains. That is a chemical finding, not a statement about the effect of CBG. A higher content makes products comparable, but not more effective in the sense of a promise. Still, looking at the certificate is worthwhile: the batch number, test date and a THC value under 0.3% show whether the information about the product is correct.

Sources

These sources support the factual statements in this article.

  1. The Origin and Biomedical Relevance of Cannabigerol (Int J Mol Sci 23(14):7929, DOI 10.3390/ijms23147929), MDPI, International Journal of Molecular Sciences (2022)Supports that CBGA is converted into precursors of CBD, THC and CBC by synthases, and that breeding lines with reduced synthase activity achieve higher CBG proportions.
  2. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives (DOI 10.1155/2022/3336516), Evidence-Based Complementary and Alternative Medicine (2022)Supports that research into CBG is predominantly preclinical and that CBG forms from CBGA through heat-induced decarboxylation.
  3. German Consumer Cannabis Act (KCanG), Section 1 Definitions, No. 9 Industrial Hemp, Federal Ministry of Justice, gesetze-im-internet.de (2024)Supports that industrial hemp in Germany is tied to varieties from the common EU variety catalogue, or to a THC content of no more than 0.3 percent.
  4. EU Plant Variety Portal: Varieties of EU-regulated agricultural, vegetable and fruit species (Art Cannabis sativa L.), European Commission, DG for Health and Food Safety (2026)Supports that Cannabis sativa L. is listed as an agricultural species in the EU variety database, where approved varieties can be looked up.
About the author

Jona Decker

Jona Decker is an author and editor specialising in CBD, cannabinoids and cannabis law. He studied business administration with a specialisation in empirical economic research and has been writing about cannabidiol since 2020. He has written for the magazine CBD360 since October 2020, where he now also co-heads the editorial team. For CBDÍA, he classifies products objectively, based on the lab certificate for each batch and documented origin.